{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:54:42Z","timestamp":1753880082044,"version":"3.41.2"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000200","name":"United States Agency for International Development","doi-asserted-by":"publisher","award":["AID-OAA-A-15-00031"],"award-info":[{"award-number":["AID-OAA-A-15-00031"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1019228"],"award-info":[{"award-number":["OPP1019228"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>\n            Etravirine (ETR) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used in treatment-experienced individuals. Genotypic resistance test-interpretation systems can predict ETR resistance; however, genotype-based algorithms are derived primarily from HIV-1 subtype B and may not accurately predict resistance in non-B subtypes. The frequency of ETR resistance among recombinant subtype C HIV-1 and the accuracy of genotypic interpretation systems were investigated. HIV-1\n            <jats:sub>LAI<\/jats:sub>\n            containing full-length RT from HIV-1 subtype C-positive individuals experiencing virologic failure (&gt;10,000 copies\/ml and &gt;1 NNRTI resistance-associated mutation) were phenotyped for ETR susceptibility.\n          <\/jats:p>","DOI":"10.1128\/aac.02101-19","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T12:07:16Z","timestamp":1582114036000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa"],"prefix":"10.1128","volume":"64","author":[{"given":"Kevin D.","family":"McCormick","sequence":"first","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerri J.","family":"Penrose","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanson J.","family":"Brumme","sequence":"additional","affiliation":[{"name":"British Columbia Centre for Excellence in HIV\/AIDS, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Richard","family":"Harrigan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel V.","family":"Viana","sequence":"additional","affiliation":[{"name":"BARC-SA and Lancet Laboratories, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Mellors","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urvi M.","family":"Parikh","sequence":"additional","affiliation":[{"name":"University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole L.","family":"Wallis","sequence":"additional","affiliation":[{"name":"BARC-SA and Lancet Laboratories, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Antiretroviral therapy coverage data and estimates by WHO region. Data HIV\/AIDS response","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Antiretroviral therapy coverage data and estimates by WHO region. Data HIV\/AIDS response. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"HIV drug resistance report","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. 2017. HIV drug resistance report. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1133927"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2017.v108i2.12573"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3231-5"},{"key":"e_1_3_3_7_2","volume-title":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61048-4"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61047-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.787411"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.20.12773-12782.2005"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt316"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2018.1510182"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/503914"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2016.0133"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0154221"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2275"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.694-701.2006"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181357"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001843"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2017.0135"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001883"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101508"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv383"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy005"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835221eb"},{"key":"e_1_3_3_27_2","unstructured":"McCormick KD Penrose KJ Brumme CJ Harrigan PR Viana RV Mellors JW Parikh UM Wallis CL. 2019. Frequent discordance between etravirine phenotype & genotype in subtype C ART failure poster 532. 2019 Conf Retrovir Opportun Infect Seattle WA."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.12.4680-4686.2004"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky256"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","unstructured":"Penrose KJ Wallis CL Sluis-Cremer N Scoulos-Hanson M Viana RV Harrigan PR Mellors JP. 2014. Frequent etravirine cross-resistance in subtype C HIV-1 isolates among first-line ART failures in South Africa. International Workshop on Antiretroviral Drug Resistance Berlin Germany.","DOI":"10.1089\/aid.2014.5346.abstract"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01805-16"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040206618762985"},{"key":"e_1_3_3_33_2","unstructured":"Rhee SY Gonzales MJ Kantor R Betts BJ Ravela JS Shafer RW. 2003. Detailed RT phenotype query. https:\/\/hivdb.stanford.edu\/cgi-bin\/RT_Phenotype.cgi. Accessed 18 April 2018."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05487-11"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30146-8"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04215-14"},{"key":"e_1_3_3_37_2","unstructured":"Vingerhoets J Monika P Hilde A Tambuyzer L Hoogstoel A Nijs S de B\u00e9thune M-P Picchio G. 2008. Tibotec etravirine weighted genotype score to predict response. XVII International HIV Drug Resistance Workshop Sitges Spain."},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/v2071476"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00348-13"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg100"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2781"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01937-15"},{"key":"e_1_3_3_43_2","unstructured":"Thermo Fisher Scientific. 2018. Ultrafast flash kinetic assays with Luminoskan and Fluoroskan FL microplate readers. Thermo Fisher Scientific Waltham MA."},{"key":"e_1_3_3_44_2","unstructured":"Coakley E Chappey C Benhamida J Picchio G Tambuyzer L Vingerhoets J deBethune M-P. 2008. Biological and clinical cut-off analyses for etravirine in the PhenoSense HIV assay. XVII International HIV Drug Resistance Workshop Sitges Spain."},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/AID.2011.0049"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2009.11.011"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bti607"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp134"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2013.03.050"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02101-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02101-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:47:55Z","timestamp":1645480075000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02101-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02101-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02101-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02101-19"}}